China
Africa
Explore chapters and articles related to this topic
Gestational Trophoblastic Neoplasia
Published in Pat Price, Karol Sikora, Treatment of Cancer, 2020
Another approach in patients with refractory disease involves high-dose chemotherapy with autologous bone marrow or peripheral stem-cell transplantation. Patient selection here is probably important in determining outcome, as has been shown for refractory germ cell tumors, where patients with drug-sensitive disease are the ones who stay in remission.163,164 In GTN, a previous report in just 11 patients suggested that high-dose chemotherapy may have little activity.165 However, more recent data in 32 cases show that high-dose chemotherapy can save about 20% of multidrug resistant GTN patients, with a further 20% being salvaged by additional treatment such as surgical resection following high dose.166 Tandem rather than high-dose procedures may offer a better chance of cure. An hCG of >12 IU/L before high-dose chemotherapy was an independent adverse prognostic factor for survival.166 However, the experience is still small, and high-dose chemotherapy is a highly toxic procedure, so alternative therapies with fewer adverse events are needed.
Hypereosinophilic syndrome
Published in Biju Vasudevan, Rajesh Verma, Dermatological Emergencies, 2019
Bone marrow transplantation (BMT), including nonmyeloablative peripheral stem cell transplantation, has been used successfully in the treatment of HES. BMT, because of high morbidity and mortality, should be reserved for patients with M-HES resistant to tyrosine kinase inhibitor therapy and patients with other forms of HES in whom end-organ damage is severe and progressive despite aggressive therapy [32].
Gestational trophoblastic neoplasia
Published in Pat Price, Karol Sikora, Treatment of Cancer, 2014
Fieke E.M. Froeling, Michael J. Seckl
Another approach in patients with refractory disease involves high dose chemotherapy with autologous bone marrow or peripheral stem-cell transplantation. Patient selection here is probably important in determining outcome as has been shown for refractory germ-cell tumours where patients with drug-sensitive disease are the ones that stay in remission.134,135 We previously reported that 5 out of
Incidence, economic burden, and treatment of acute respiratory tract infection in hematopoietic stem cell transplantation recipients using real world data in Japan: a retrospective claims data analysis
Published in Journal of Medical Economics, 2022
Kittima Wattanakamolkul, Yoshikazu Nakayama
Patients receiving HSCT including bone marrow transplantation, peripheral stem cell transplantation, cord blood transplantation, autotransplantation, and allotransplantation, as defined by the medical procedure code (Supplementary Table S1) during the identification period, and those who were enrolled in the JMDC database for at least 6 months prior to the index month, i.e. the month of latest HSCT, were included in the study. Patients had to remain enrolled in the JMDC database until completion of the hospitalization after HSCT and for at least 1 month post-discharge to be included in the analysis. Patients with HSCT at index month who were recorded on outpatient claim were excluded. The patient confidentiality was maintained as the patients’ data were anonymized and no patient identifiers were used, hence, the study is exempt from review by institutional review board.
Exercise interventions to combat cancer-related fatigue in cancer patients undergoing treatment: a review
Published in Cancer Investigation, 2022
Selecting appropriate exercise type and intensity for advanced cancer patients can be difficult. 30 min of moderate intensity seated exercise, three times per week, has been shown to have a significant impact on the fatigue levels of women with metastatic breast cancer (56). Women with metastatic breast cancer, scheduled for chemotherapy, were randomized to a usual care group and an exercise group. The levels of fatigue for the entire sample significantly increased as they progressed through chemotherapy. However, the exercise group exhibited significantly less fatigue than the usual care group. Overall adherence rate was 75%. A common theme among women in the exercise group was that the seated exercise was not sufficiently physically challenging. A similar study by Dimeo et al. (57) investigated the effect of 30 min of interval bed cycling (50% of heart rate reserve) on fatigue in cancer patients receiving high-dose chemotherapy followed by peripheral stem cell transplantation. Unlike Headley et al. (56), patients performing bed ergometer exercise were in hospital. About 82% adherence rate was noted, and the exercise group displayed no increase in fatigue whereas the control exhibited a significant increase in fatigue.
SEIFEM 2017: from real life to an agreement on the use of granulocyte transfusions and colony-stimulating factors for prophylaxis and treatment of infectious complications in patients with hematologic malignant disorders
Published in Expert Review of Hematology, 2018
Alessandro Busca, Simone Cesaro, Luciana Teofili, Mario Delia, Chiara Cattaneo, Marianna Criscuolo, Francesco Marchesi, Nicola Stefano Fracchiolla, Caterina Giovanna Valentini, Francesca Farina, Roberta Di Blasi, Lucia Prezioso, Angelica Spolzino, Anna Candoni, Maria Ilaria del Principe, Luisa Verga, Annamaria Nosari, Franco Aversa, Livio Pagano
In order to assess the real-life clinical practice for the use of G-CSF in patients with myeloproliferative and lymphoproliferative diseases among Italian hematology centers participating to the SEIFEM network, we performed a survey from November to December 2016, among 21 hematology centers, including 17 adult and 3 pediatric centers, and 1 mixed center with adult and pediatric patients. The expertise of these centers is documented by annual figures of activity. In fact, these centers account for 4365 new diagnoses per year distributed as follows: non-Hodgkin lymphomas (NHL) 1619, acute myeloid leukemia (AML) 597, MDS 553, multiple Myeloma (MM) 550, CLL 512, Hodgkin lymphoma (HL) 339, and acute lymphoblastic leukemia (ALL) 195. Moreover, these centers performed yearly 755 autologous peripheral stem cell transplantation (auto-PBSC), 330 allogeneic PBSC (allo-PBSC), 180 allogeneic bone marrow transplantations (allo-BMT), and 7 auto-BMT. Interestingly, 15 of 21 centers (71%) had restrictions to prescribe the molecule of G-CSF originator, or it was not available in the hospital pharmacy, whereas peg-filgrastim originator molecule was available only in 17 centers but in 8 of them (53%) there was an internal restriction to the prescription. Overall, the internal hospital policies regarding the prescription of G-CSF originator molecules or of peg-filgrastim were in favor of G-CSF biosimilars to reduce the burden of annual pharmacy costs. In fact, 60% of centers declared that the utilization of biosimilars instead of originator molecules of G-CSF was a criteria included in the hospital annual evaluation of the resource utilization by the hematology unit.